KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Gains from Investment Securities (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Gains from Investment Securities data on record, last reported at -$11000.0 in Q3 2025.

  • For Q3 2025, Gains from Investment Securities fell 100.98% year-over-year to -$11000.0; the TTM value through Sep 2025 reached -$1.2 million, down 208.37%, while the annual FY2024 figure was -$104000.0, 1045.45% down from the prior year.
  • Gains from Investment Securities reached -$11000.0 in Q3 2025 per AQST's latest filing, up from -$1.5 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.5 million in Q1 2025 and bottomed at -$1.5 million in Q2 2025.
  • Average Gains from Investment Securities over 5 years is -$4222.2, with a median of $0.0 recorded in 2023.
  • The widest YoY moves for Gains from Investment Securities: up 4865.62% in 2025, down 11746.15% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at -$234000.0 in 2021, then surged by 126.92% to $63000.0 in 2022, then plummeted by 82.54% to $11000.0 in 2023, then tumbled by 11045.45% to -$1.2 million in 2024, then skyrocketed by 99.09% to -$11000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$11000.0 in Q3 2025, -$1.5 million in Q2 2025, and $1.5 million in Q1 2025.